CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial Left atrial appendage occlusion in atrial fibrillation patients with previous intracranial bleeding: A national multicenter study Comprehensive Investigation of Circulating Biomarkers and their Causal Role in Atherosclerosis-related Risk Factors and Clinical Events Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention Feasibility and efficacy of the ultrashort side branch dedicated balloon in coronary bifurcation stenting Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers Low Endothelial Shear Stress Predicts Evolution to High-Risk Coronary Plaque Phenotype in the Future: A Serial Optical Coherence Tomography and Computational Fluid Dynamics Study

Clinical TrialVolume 72, Issue 23 Part A, December 2018

JOURNAL:J Am Coll Cardiol. Article Link

10-Year Outcomes of Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease

DW Park, JM Ahn, SC Yun et al. Keywords: bypass surgery; coronary artery disease; left main coronary artery disease; stents

ABSTRACT


BACKGROUND - Comparative outcomes of coronary-artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for left main coronary artery (LMCA) disease were previously reported. However, data on very long-term (>10 years) outcomes are limited.

 

OBJECTIVE - To compare 10-year outcomes after PCI and CABG for LMCA disease.

 

METHODS - In this observational study of the MAINCOMPARE registry, we evaluated 2240 patients with unprotected LMCA disease who underwent PCI (n=1102) or underwent CABG (n=1138) between January 2000 and June 2006. Adverse outcomes (death; a composite outcome of death, Q-wave myocardial infarction, or stroke; and target-vessel revascularization) were compared with the use of propensity scores and inverse-probability-weighting adjustment. The follow-up was extended to at least 10 years of all patients (median, 12.0 years).

 

RESULTS - In the overall cohort, there was no significant difference in adjusted risks of death and the composite outcome between the groups up to 10 years. The risk of target-vessel revascularization was significantly higher in the PCI group. In the cohort comparing drug-eluting stents and concurrent CABG, the two study groups did not differ significantly in the risks of death and the composite outcome at 5 years. However, after 5 years, drug-eluting stents were associated with higher risks of death (hazard ratio [HR], 1.35; 95% confidence interval [CI], 1.00-1.81) and the composite outcome (HR, 1.46; 95% CI, 1.10-1.94) compared to CABG.

 

CONCLUSIONS - In patients with significant LMCA disease, as compared with CABG, PCI showed similar rates of death and serious composite outcome, but a higher rate of target-vessel revascularization at 10 years. However, CABG showed lower mortality and serious composite outcome rates compared to PCI with drug-eluting stents after 5 years.

 

Copyright © 2018. Published by Elsevier Inc.